Prostate hyperplasia therapy

Details Prostate hyperplasia therapy Prostate hyperplasia therapy

2008-01-01

2008-01-01

Tsang, Cecilia J. (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Insulin; related peptides

Reexamination Certificate

active

07314911

ABSTRACT:
The invention is a method for treating prostate hyperplasia by contacting a patient with insulin-6 in an amount effective to prevent or reduce prostate hyperplasia. The invention includes transgenic insulin-6 knockout mice that exhibit prostate hyperplasia and that can be used in screening agents for anti-prostate hyperplasia activity.

REFERENCES:
Lamb DJ, Zhang L Challenges in prostate cancer research: animal models for nutritional studies of chemoprevention and disease progression. J. Nutr. Dec. 2005;135(12 Suppl):3009S-3015S.
Carlson GA, Borchelt DR, Dake A, Turner S, Danielson V, Coffin JD, Eckman C, Meiners J, Nilsen SP, Younkin SG, Hsiao KK., Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice, Hum Mol Genet. 1997.
Lok S., et al, “Identification of INSL6, a new member of the insulin family that is expressed in the testis of the human and rat,” Biol Reprod. Jun. 2000;62(6):1593-9.

Affiliated with

Also associated with

Rating

Prostate hyperplasia therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prostate hyperplasia therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prostate hyperplasia therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2772094